anti scd1 (Cell Signaling Technology Inc)
Cell Signaling Technology Inc is a verified supplier 
Cell Signaling Technology Inc manufactures this product 
95
Structured Review
Cell Signaling Technology Inc
anti scd1
Anti Scd1, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 95/100, based on 224 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/scd1/SCD1+Rabbit+mAb/pm41935215-265-21-22
Average 95 stars, based on 224 article reviews
Anti Scd1, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 95/100, based on 224 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/scd1/SCD1+Rabbit+mAb/pm41935215-265-21-22
Average 95 stars, based on 224 article reviews
anti scd1 - by Bioz Stars,
2026-09
95/100 stars
Images
Related Articles
Staining:Article Title: A novel arctigenin derivative attenuates nonalcoholic fatty liver disease by activating adiponectin receptor 1-mediated AMPK signaling pathway. Article Snippet: Nonalcoholic fatty liver disease (NAFLD), along with metabolic syndrome and obesity, has seen a dramatic rise in frequency around the world.. Arctigenin (ATG) has better efficacy in the treatment of non-alcoholic fatty liver in vitro, but its application in vivo models is limited due to its low oral bioavailability and poor water solubility.. Compound ARC-18 is a derivative of ATG. Article Title: RNF186 controls glucose metabolism in metabolic dysfunction-associated fatty liver disease. Article Snippet: Primary antibodies specific for the following proteins were purchased from Cell Culture:Article Title: A novel arctigenin derivative attenuates nonalcoholic fatty liver disease by activating adiponectin receptor 1-mediated AMPK signaling pathway. Article Snippet: Nonalcoholic fatty liver disease (NAFLD), along with metabolic syndrome and obesity, has seen a dramatic rise in frequency around the world.. Arctigenin (ATG) has better efficacy in the treatment of non-alcoholic fatty liver in vitro, but its application in vivo models is limited due to its low oral bioavailability and poor water solubility.. Compound ARC-18 is a derivative of ATG. Article Title: RNF186 controls glucose metabolism in metabolic dysfunction-associated fatty liver disease. Article Snippet: Primary antibodies specific for the following proteins were purchased from Western Blot:Article Title: A novel arctigenin derivative attenuates nonalcoholic fatty liver disease by activating adiponectin receptor 1-mediated AMPK signaling pathway. Article Snippet: Nonalcoholic fatty liver disease (NAFLD), along with metabolic syndrome and obesity, has seen a dramatic rise in frequency around the world.. Arctigenin (ATG) has better efficacy in the treatment of non-alcoholic fatty liver in vitro, but its application in vivo models is limited due to its low oral bioavailability and poor water solubility.. Compound ARC-18 is a derivative of ATG. Article Title: RNF186 controls glucose metabolism in metabolic dysfunction-associated fatty liver disease. Article Snippet: Primary antibodies specific for the following proteins were purchased from Gene Expression:Article Title: A novel arctigenin derivative attenuates nonalcoholic fatty liver disease by activating adiponectin receptor 1-mediated AMPK signaling pathway. Article Snippet: Nonalcoholic fatty liver disease (NAFLD), along with metabolic syndrome and obesity, has seen a dramatic rise in frequency around the world.. Arctigenin (ATG) has better efficacy in the treatment of non-alcoholic fatty liver in vitro, but its application in vivo models is limited due to its low oral bioavailability and poor water solubility.. Compound ARC-18 is a derivative of ATG. Article Title: RNF186 controls glucose metabolism in metabolic dysfunction-associated fatty liver disease. Article Snippet: Primary antibodies specific for the following proteins were purchased from Transplantation Assay:Article Title: A novel arctigenin derivative attenuates nonalcoholic fatty liver disease by activating adiponectin receptor 1-mediated AMPK signaling pathway. Article Snippet: Nonalcoholic fatty liver disease (NAFLD), along with metabolic syndrome and obesity, has seen a dramatic rise in frequency around the world.. Arctigenin (ATG) has better efficacy in the treatment of non-alcoholic fatty liver in vitro, but its application in vivo models is limited due to its low oral bioavailability and poor water solubility.. Compound ARC-18 is a derivative of ATG. Article Title: RNF186 controls glucose metabolism in metabolic dysfunction-associated fatty liver disease. Article Snippet: Primary antibodies specific for the following proteins were purchased from Expressing:Article Title: A novel arctigenin derivative attenuates nonalcoholic fatty liver disease by activating adiponectin receptor 1-mediated AMPK signaling pathway. Article Snippet: Nonalcoholic fatty liver disease (NAFLD), along with metabolic syndrome and obesity, has seen a dramatic rise in frequency around the world.. Arctigenin (ATG) has better efficacy in the treatment of non-alcoholic fatty liver in vitro, but its application in vivo models is limited due to its low oral bioavailability and poor water solubility.. Compound ARC-18 is a derivative of ATG. Article Title: RNF186 controls glucose metabolism in metabolic dysfunction-associated fatty liver disease. Article Snippet: Primary antibodies specific for the following proteins were purchased from Inhibition:Article Title: A novel arctigenin derivative attenuates nonalcoholic fatty liver disease by activating adiponectin receptor 1-mediated AMPK signaling pathway. Article Snippet: Nonalcoholic fatty liver disease (NAFLD), along with metabolic syndrome and obesity, has seen a dramatic rise in frequency around the world.. Arctigenin (ATG) has better efficacy in the treatment of non-alcoholic fatty liver in vitro, but its application in vivo models is limited due to its low oral bioavailability and poor water solubility.. Compound ARC-18 is a derivative of ATG. Article Title: RNF186 controls glucose metabolism in metabolic dysfunction-associated fatty liver disease. Article Snippet: Primary antibodies specific for the following proteins were purchased from In Vitro:Article Title: A novel arctigenin derivative attenuates nonalcoholic fatty liver disease by activating adiponectin receptor 1-mediated AMPK signaling pathway. Article Snippet: Nonalcoholic fatty liver disease (NAFLD), along with metabolic syndrome and obesity, has seen a dramatic rise in frequency around the world.. Arctigenin (ATG) has better efficacy in the treatment of non-alcoholic fatty liver in vitro, but its application in vivo models is limited due to its low oral bioavailability and poor water solubility.. Compound ARC-18 is a derivative of ATG. Article Title: RNF186 controls glucose metabolism in metabolic dysfunction-associated fatty liver disease. Article Snippet: Primary antibodies specific for the following proteins were purchased from Control:Article Title: A novel arctigenin derivative attenuates nonalcoholic fatty liver disease by activating adiponectin receptor 1-mediated AMPK signaling pathway. Article Snippet: Nonalcoholic fatty liver disease (NAFLD), along with metabolic syndrome and obesity, has seen a dramatic rise in frequency around the world.. Arctigenin (ATG) has better efficacy in the treatment of non-alcoholic fatty liver in vitro, but its application in vivo models is limited due to its low oral bioavailability and poor water solubility.. Compound ARC-18 is a derivative of ATG. Article Title: RNF186 controls glucose metabolism in metabolic dysfunction-associated fatty liver disease. Article Snippet: Primary antibodies specific for the following proteins were purchased from Colorimetric Assay:Article Title: A novel arctigenin derivative attenuates nonalcoholic fatty liver disease by activating adiponectin receptor 1-mediated AMPK signaling pathway. Article Snippet: Nonalcoholic fatty liver disease (NAFLD), along with metabolic syndrome and obesity, has seen a dramatic rise in frequency around the world.. Arctigenin (ATG) has better efficacy in the treatment of non-alcoholic fatty liver in vitro, but its application in vivo models is limited due to its low oral bioavailability and poor water solubility.. Compound ARC-18 is a derivative of ATG. Article Title: RNF186 controls glucose metabolism in metabolic dysfunction-associated fatty liver disease. Article Snippet: Primary antibodies specific for the following proteins were purchased from Flow Cytometry:Article Title: A novel arctigenin derivative attenuates nonalcoholic fatty liver disease by activating adiponectin receptor 1-mediated AMPK signaling pathway. Article Snippet: Nonalcoholic fatty liver disease (NAFLD), along with metabolic syndrome and obesity, has seen a dramatic rise in frequency around the world.. Arctigenin (ATG) has better efficacy in the treatment of non-alcoholic fatty liver in vitro, but its application in vivo models is limited due to its low oral bioavailability and poor water solubility.. Compound ARC-18 is a derivative of ATG. Article Title: RNF186 controls glucose metabolism in metabolic dysfunction-associated fatty liver disease. Article Snippet: Primary antibodies specific for the following proteins were purchased from Injection:Article Title: A novel arctigenin derivative attenuates nonalcoholic fatty liver disease by activating adiponectin receptor 1-mediated AMPK signaling pathway. Article Snippet: Nonalcoholic fatty liver disease (NAFLD), along with metabolic syndrome and obesity, has seen a dramatic rise in frequency around the world.. Arctigenin (ATG) has better efficacy in the treatment of non-alcoholic fatty liver in vitro, but its application in vivo models is limited due to its low oral bioavailability and poor water solubility.. Compound ARC-18 is a derivative of ATG. Article Title: RNF186 controls glucose metabolism in metabolic dysfunction-associated fatty liver disease. Article Snippet: Primary antibodies specific for the following proteins were purchased from Immunohistochemical staining:Article Title: A novel arctigenin derivative attenuates nonalcoholic fatty liver disease by activating adiponectin receptor 1-mediated AMPK signaling pathway. Article Snippet: Nonalcoholic fatty liver disease (NAFLD), along with metabolic syndrome and obesity, has seen a dramatic rise in frequency around the world.. Arctigenin (ATG) has better efficacy in the treatment of non-alcoholic fatty liver in vitro, but its application in vivo models is limited due to its low oral bioavailability and poor water solubility.. Compound ARC-18 is a derivative of ATG. Article Title: RNF186 controls glucose metabolism in metabolic dysfunction-associated fatty liver disease. Article Snippet: Primary antibodies specific for the following proteins were purchased from Methylation:Article Title: A novel arctigenin derivative attenuates nonalcoholic fatty liver disease by activating adiponectin receptor 1-mediated AMPK signaling pathway. Article Snippet: Nonalcoholic fatty liver disease (NAFLD), along with metabolic syndrome and obesity, has seen a dramatic rise in frequency around the world.. Arctigenin (ATG) has better efficacy in the treatment of non-alcoholic fatty liver in vitro, but its application in vivo models is limited due to its low oral bioavailability and poor water solubility.. Compound ARC-18 is a derivative of ATG. Article Title: RNF186 controls glucose metabolism in metabolic dysfunction-associated fatty liver disease. Article Snippet: Primary antibodies specific for the following proteins were purchased from Modification:Article Title: A novel arctigenin derivative attenuates nonalcoholic fatty liver disease by activating adiponectin receptor 1-mediated AMPK signaling pathway. Article Snippet: Nonalcoholic fatty liver disease (NAFLD), along with metabolic syndrome and obesity, has seen a dramatic rise in frequency around the world.. Arctigenin (ATG) has better efficacy in the treatment of non-alcoholic fatty liver in vitro, but its application in vivo models is limited due to its low oral bioavailability and poor water solubility.. Compound ARC-18 is a derivative of ATG. Article Title: RNF186 controls glucose metabolism in metabolic dysfunction-associated fatty liver disease. Article Snippet: Primary antibodies specific for the following proteins were purchased from Quantitative RT-PCR:Article Title: A novel arctigenin derivative attenuates nonalcoholic fatty liver disease by activating adiponectin receptor 1-mediated AMPK signaling pathway. Article Snippet: Nonalcoholic fatty liver disease (NAFLD), along with metabolic syndrome and obesity, has seen a dramatic rise in frequency around the world.. Arctigenin (ATG) has better efficacy in the treatment of non-alcoholic fatty liver in vitro, but its application in vivo models is limited due to its low oral bioavailability and poor water solubility.. Compound ARC-18 is a derivative of ATG. Article Title: RNF186 controls glucose metabolism in metabolic dysfunction-associated fatty liver disease. Article Snippet: Primary antibodies specific for the following proteins were purchased from Marker:Article Title: A novel arctigenin derivative attenuates nonalcoholic fatty liver disease by activating adiponectin receptor 1-mediated AMPK signaling pathway. Article Snippet: Nonalcoholic fatty liver disease (NAFLD), along with metabolic syndrome and obesity, has seen a dramatic rise in frequency around the world.. Arctigenin (ATG) has better efficacy in the treatment of non-alcoholic fatty liver in vitro, but its application in vivo models is limited due to its low oral bioavailability and poor water solubility.. Compound ARC-18 is a derivative of ATG. Article Title: RNF186 controls glucose metabolism in metabolic dysfunction-associated fatty liver disease. Article Snippet: Primary antibodies specific for the following proteins were purchased from Luciferase:Article Title: A novel arctigenin derivative attenuates nonalcoholic fatty liver disease by activating adiponectin receptor 1-mediated AMPK signaling pathway. Article Snippet: Nonalcoholic fatty liver disease (NAFLD), along with metabolic syndrome and obesity, has seen a dramatic rise in frequency around the world.. Arctigenin (ATG) has better efficacy in the treatment of non-alcoholic fatty liver in vitro, but its application in vivo models is limited due to its low oral bioavailability and poor water solubility.. Compound ARC-18 is a derivative of ATG. Article Title: RNF186 controls glucose metabolism in metabolic dysfunction-associated fatty liver disease. Article Snippet: Primary antibodies specific for the following proteins were purchased from Membrane:Article Title: A novel arctigenin derivative attenuates nonalcoholic fatty liver disease by activating adiponectin receptor 1-mediated AMPK signaling pathway. Article Snippet: Nonalcoholic fatty liver disease (NAFLD), along with metabolic syndrome and obesity, has seen a dramatic rise in frequency around the world.. Arctigenin (ATG) has better efficacy in the treatment of non-alcoholic fatty liver in vitro, but its application in vivo models is limited due to its low oral bioavailability and poor water solubility.. Compound ARC-18 is a derivative of ATG. Article Title: RNF186 controls glucose metabolism in metabolic dysfunction-associated fatty liver disease. Article Snippet: Primary antibodies specific for the following proteins were purchased from Transmission Assay:Article Title: A novel arctigenin derivative attenuates nonalcoholic fatty liver disease by activating adiponectin receptor 1-mediated AMPK signaling pathway. Article Snippet: Nonalcoholic fatty liver disease (NAFLD), along with metabolic syndrome and obesity, has seen a dramatic rise in frequency around the world.. Arctigenin (ATG) has better efficacy in the treatment of non-alcoholic fatty liver in vitro, but its application in vivo models is limited due to its low oral bioavailability and poor water solubility.. Compound ARC-18 is a derivative of ATG. Article Title: RNF186 controls glucose metabolism in metabolic dysfunction-associated fatty liver disease. Article Snippet: Primary antibodies specific for the following proteins were purchased from Electron Microscopy:Article Title: A novel arctigenin derivative attenuates nonalcoholic fatty liver disease by activating adiponectin receptor 1-mediated AMPK signaling pathway. Article Snippet: Nonalcoholic fatty liver disease (NAFLD), along with metabolic syndrome and obesity, has seen a dramatic rise in frequency around the world.. Arctigenin (ATG) has better efficacy in the treatment of non-alcoholic fatty liver in vitro, but its application in vivo models is limited due to its low oral bioavailability and poor water solubility.. Compound ARC-18 is a derivative of ATG. Article Title: RNF186 controls glucose metabolism in metabolic dysfunction-associated fatty liver disease. Article Snippet: Primary antibodies specific for the following proteins were purchased from Over Expression:Article Title: A novel arctigenin derivative attenuates nonalcoholic fatty liver disease by activating adiponectin receptor 1-mediated AMPK signaling pathway. Article Snippet: Nonalcoholic fatty liver disease (NAFLD), along with metabolic syndrome and obesity, has seen a dramatic rise in frequency around the world.. Arctigenin (ATG) has better efficacy in the treatment of non-alcoholic fatty liver in vitro, but its application in vivo models is limited due to its low oral bioavailability and poor water solubility.. Compound ARC-18 is a derivative of ATG. Article Title: RNF186 controls glucose metabolism in metabolic dysfunction-associated fatty liver disease. Article Snippet: Primary antibodies specific for the following proteins were purchased from Immunohistochemistry:Article Title: A novel arctigenin derivative attenuates nonalcoholic fatty liver disease by activating adiponectin receptor 1-mediated AMPK signaling pathway. Article Snippet: Nonalcoholic fatty liver disease (NAFLD), along with metabolic syndrome and obesity, has seen a dramatic rise in frequency around the world.. Arctigenin (ATG) has better efficacy in the treatment of non-alcoholic fatty liver in vitro, but its application in vivo models is limited due to its low oral bioavailability and poor water solubility.. Compound ARC-18 is a derivative of ATG. Article Title: RNF186 controls glucose metabolism in metabolic dysfunction-associated fatty liver disease. Article Snippet: Primary antibodies specific for the following proteins were purchased from |
